Investing.com - Standard Biotools (NASDAQ: LAB) reported first quarter EPS of $-0.110, $0.05 worse than the analyst estimate of $-0.060. Revenue for the quarter came in at $25.12M versus the consensus estimate of $28.36M.
Standard Biotools's stock price closed at $1.600. It is down -21.950% in the last 3 months and down -35.160% in the last 12 months.
Standard Biotools saw positive EPS revisions and negative EPS revisions in the last 90 days. See Standard Biotools's stock price’s past reactions to earnings here.
According to InvestingPro, Standard Biotools's Financial Health score is "weak performance".
Check out Standard Biotools's recent earnings performance, and Standard Biotools's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar